LUBIPROSTONE (lubiprostone) by Pfizer is chloride channel activators [moa]. Approved for chronic idiopathic constipation (cic) in adults, opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer and 3 more indications. First approved in 2022.
Drug data last refreshed 19h ago
Chloride Channel Activators
Worked on LUBIPROSTONE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Lubiprostone to Treat Constipation
Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers
Lubiprostone for Chronic Idiopathic Constipation Treatment
Lubiprostone for Treatment of Chronic Idiopathic Constipation
Lubiprostone for the Treatment of Chronic Idiopathic Constipation